MedRx Co., Ltd
Notice Regarding Change of Market Segment to the Tokyo Stock Exchange “Standard” Market
On 2026-10-07, the company changed its market segment from the Tokyo Stock Exchange Growth Market to the Standard Market. There is no change in growth or R&D policy; the company confirms it will continue drug development leveraging its proprietary formulation technology.
Key Figures
- Unknown: Revenue
- Unknown: Operating Income
- Unknown: Net Income
AI要約
Overview of Market Segment Change
Today, the company announced the change from the TSE Growth Market to the Standard Market. The change does not alter the company's growth strategy or R&D policy, and the company confirms it will continue to promote drug development using its proprietary formulation technology. The company communicates to investors that it will continue to pursue sustainable enhancement of corporate value.
Outlook and Request for Support
In connection with the market segment change, there is no change to the growth strategy or long-term plan, and the company asks for continued support and understanding. The disclosed information is limited to the facts regarding the market segment change and does not include specific financial indicators such as performance figures, dividends, or capital policy in this document.
MedRx Co., Ltd
Company overview · Stock price · Financial data · All IR
